Country: Canada
Language: English
Source: Health Canada
HEPATITIS B SURFACE ANTIGEN (RECOMBINANT)
MERCK CANADA INC
J07BC01
HEPATITIS B, PURIFIED ANTIGEN
10MCG
SOLUTION
HEPATITIS B SURFACE ANTIGEN (RECOMBINANT) 10MCG
INTRAMUSCULAR
3ML/10X3ML
Schedule D
VACCINES
Active ingredient group (AIG) number: 0119570001; AHFS:
CANCELLED POST MARKET
2010-03-08
_ Product Monograph – RECOMBIVAX HB_ _®_ _ _ _Page 1 of 25_ PRODUCT MONOGRAPH RECOMBIVAX HB ® (hepatitis B vaccine [recombinant]) Suspension for Injection Vaccine for immunization against infection caused by hepatitis B virus including all known subtypes MERCK FROSST CANADA LTD. 16711 Trans Canada Highway Kirkland QC H9H 3L1 Canada www.merckfrosst.com Date of Revision: GLOBAL TRADE IDENTIFICATION NO.: Pediatric: 0 67055 04523 3 (1 x 0.5 mL) Adult: 0 67055 04569 1 (1 x 1 mL); 0 67055 04633 9 (10 x 1 mL) Adult: 0 67055 03811 2 (1 x 3 mL); 0 67055 04302 4 (1 x 10 mL) Adult Dialysis: 0 67055 04569 1 (1 x 1 mL) SUBMISSION CONTROL NO: 126922 APPROVED: MARCH 23, 2009 RECOMBIVAX HB ® is a Registered Trademark of Merck & Co., Inc. Used under license. _ _ _Product Monograph – RECOMBIVAX HB_ _®_ _ _ _Page 2 of 25_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 DESCRIPTION....................................................................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS..................................................................................5 ADVERSE REACTIONS....................................................................................................6 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION..............................................................................11 OVERDOSAGE ................................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY ........................................ Read the complete document